Abbott Introduces Canada's First Remote Neuromodulation Patient-Care Technology, NeuroSphere Virtual Clinic, to Treat People with Chronic Pain and Movement Disorders* Pharmaceutical Investing
European Commission Approves RINVOQ® for the Treatment of Adults With Moderate to Severe Ulcerative Colitis Pharmaceutical Investing
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 Pharmaceutical Investing
AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference Pharmaceutical Investing
Kite's CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia Pharmaceutical Investing
CHMP Adopts Positive Opinion Recommending Veklury® Receive Full Marketing Authorization for the Treatment of Patients With COVID-19 Pharmaceutical Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag for Treatment of Patients with Unresectable or Metastatic Melanoma Pharmaceutical Investing
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® for the Treatment of Adults with Active Lupus Nephritis in Europe Pharmaceutical Investing
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic Pharmaceutical Investing
Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry Pharmaceutical Investing
